Stock Track | Royalty Pharma Soars on Raised Full-Year Guidance Despite Q3 Revenue Miss

Stock Track11-06

Shares of Royalty Pharma plc (NASDAQ: RPRX) surged over 5% in pre-market trading on Monday, following the biopharmaceutical company's mixed third-quarter earnings report and raised full-year guidance.

For the third quarter of fiscal 2024, Royalty Pharma reported adjusted earnings per share of $1.04, beating Wall Street's expectations of $0.93. However, the company's revenue came in at $565 million, falling short of analysts' estimates of $696.1 million, though it represented a 5.41% increase compared to the same period last year.

Despite the revenue miss, investors were encouraged by Royalty Pharma's decision to raise its full-year 2024 portfolio receipts guidance to a range of $2.75 billion to $2.8 billion. This upward revision reflects the company's confidence in its diversified portfolio of royalty interests in various pharmaceutical products.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140912746?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140912746","market":"hk","top_or_hot":-1,"title":"Stock Track | Royalty Pharma Soars on Raised Full-Year Guidance Despite Q3 Revenue Miss","media":"Stock Track","content":"<p>Shares of Royalty Pharma plc (NASDAQ: RPRX) surged over 5% in pre-market trading on Monday, following the biopharmaceutical company's mixed third-quarter earnings report and raised full-year guidance.</p>\n\n<p>For the third quarter of fiscal 2024, Royalty Pharma reported adjusted earnings per share of $1.04, beating Wall Street's expectations of $0.93. However, the company's revenue came in at $565 million, falling short of analysts' estimates of $696.1 million, though it represented a 5.41% increase compared to the same period last year.</p>\n\n<p>Despite the revenue miss, investors were encouraged by Royalty Pharma's decision to raise its full-year 2024 portfolio receipts guidance to a range of $2.75 billion to $2.8 billion. This upward revision reflects the company's confidence in its diversified portfolio of royalty interests in various pharmaceutical products.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Royalty Pharma Soars on Raised Full-Year Guidance Despite Q3 Revenue Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Royalty Pharma Soars on Raised Full-Year Guidance Despite Q3 Revenue Miss\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-06 21:04 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Royalty Pharma plc (NASDAQ: RPRX) surged over 5% in pre-market trading on Monday, following the biopharmaceutical company's mixed third-quarter earnings report and raised full-year guidance....</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RPRX","symbol_name":"Royalty Pharma plc","start_time":0,"source_url":"","article_id":"1140912746","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140912746","pubTimestamp":1730898244,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Royalty Pharma plc  surged over 5% in pre-market trading on Monday, following the biopharmaceutical company's mixed third-quarter earnings report and raised full-year guidance.For the third quarter of fiscal 2024, Royalty Pharma reported adjusted earnings per share of $1.04, beating Wall Street's expectations of $0.93. However, the company's revenue came in at $565 million, falling short of analysts' estimates of $696.1 million, though it represented a 5.41% increase compared to the sa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RPRX":"Royalty Pharma plc"},"translate_title":"尽管第三季度收入未达预期，Royalty Pharma仍因提高全年指引而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RPRX":1},"content_text":"Shares of Royalty Pharma plc (NASDAQ: RPRX) surged over 5% in pre-market trading on Monday, following the biopharmaceutical company's mixed third-quarter earnings report and raised full-year guidance.\nFor the third quarter of fiscal 2024, Royalty Pharma reported adjusted earnings per share of $1.04, beating Wall Street's expectations of $0.93. However, the company's revenue came in at $565 million, falling short of analysts' estimates of $696.1 million, though it represented a 5.41% increase compared to the same period last year.\nDespite the revenue miss, investors were encouraged by Royalty Pharma's decision to raise its full-year 2024 portfolio receipts guidance to a range of $2.75 billion to $2.8 billion. This upward revision reflects the company's confidence in its diversified portfolio of royalty interests in various pharmaceutical products.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140912746"}